Aldeyra Therapeutics (NASDAQ:ALDX) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Aldeyra Therapeutics (NASDAQ:ALDX) from a hold rating to a sell rating in a research report released on Saturday morning.

Separately, Weiss Ratings cut shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.50.

Aldeyra Therapeutics Trading Up 8.3%

ALDX opened at $1.56 on Friday. The stock’s 50 day simple moving average is $1.81 and its 200-day simple moving average is $2.61. The stock has a market cap of $94.11 million, a PE ratio of -4.00 and a beta of 1.21. Aldeyra Therapeutics has a 1 year low of $1.07 and a 1 year high of $6.17.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Equities analysts forecast that Aldeyra Therapeutics will post -0.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Aldeyra Therapeutics

In related news, CEO Todd C. Brady bought 250,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $1.67 per share, with a total value of $417,500.00. Following the acquisition, the chief executive officer owned 1,721,298 shares in the company, valued at approximately $2,874,567.66. This represents a 16.99% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 11.80% of the company’s stock.

Institutional Trading of Aldeyra Therapeutics

Institutional investors have recently bought and sold shares of the stock. Abel Hall LLC bought a new stake in Aldeyra Therapeutics in the first quarter valued at $26,000. Krilogy Financial LLC bought a new position in shares of Aldeyra Therapeutics during the first quarter valued at $26,000. Chicago Partners Investment Group LLC bought a new position in shares of Aldeyra Therapeutics during the first quarter valued at $33,000. Hikari Power Ltd acquired a new stake in shares of Aldeyra Therapeutics in the 2nd quarter valued at $43,000. Finally, Caption Management LLC boosted its stake in shares of Aldeyra Therapeutics by 110.6% in the 2nd quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 132,358 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.